期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

慢性淋巴细胞白血病生物学预后指标的研究进展 被引量：2

Advances in biological prognostic indicators of chronic lymphocytic leukemia
原文传递
导出
摘要 慢性淋巴细胞白血病（CLL）预后个体差异大，在诊断初期对患者进行准确的预后判断，进而辅助制定治疗计划具有重要临床意义。近年来CLL预后指标如IsVH基因突变，ZAP70，CD。细胞遗传学异新t（11q；v）、del（11q）、del（17p）、＋12和del（13q）]，端粒和端粒酶等成为研究的热点，文章就其研究的新进展进行综述。 The patients of chronic lymphocytic leukemia （CLL） have great individual differences. It is important for clinicians to determine the prognosis at the beginning of diagnosis and choose proper treatment for the patients. The recent advances in biological prognostic indicators of CLL were reviewed, including IgVH gene mutation status, ZAPTO, CD3s, chromosome abnormality [t（11q;v）, del（11q）, del（17p）, ＋12 and del（13q）], telomere and telornerase.
作者 马兰(综述) 王晶(综述) 克晓燕(审校)
机构地区 北京大学第三医院血液科
出处 《白血病．淋巴瘤》 CAS 2010年第1期55-58,共4页 Journal of Leukemia & Lymphoma
关键词 白血病 淋巴细胞 预后 生物学 Leukemia, lymphocytic Prognosis Biology
分类号 R733.72 [医药卫生—肿瘤] R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献32

  • 1Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood, 1999, 94: 1848-1854.
  • 2Damle RN, Wasil T, Fais F, et al.Ig VH gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood, 1999, 94: 1840-1847.
  • 3Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with chronic lymphcytic leukemia. Blood, 2004, 103: 1202-1210.
  • 4Kharfan-Dabaja MA, Chavez JC, Khorfan KA, et al. Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. Cancer, 2008, 113: 897-906.
  • 5Chen L, Widhopf G, Huynh L, et al. Expression of ZAP 70 is associated with increased B-cell receptor signaling in ehronie lymphocytic leukemia. Blood, 2002, 100: 4609-4914.
  • 6Lin KI, Tam CS, Keating MJ, et al. Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens.Blood, 2009, 113:3168-3171.
  • 7Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med, 2001, 194: 1639- 1647.
  • 8Rassenti LZ, Huynh L, Tay TL, et al. ZAP 70 compared with immunog/obulin heavy chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med, 2004, 351: 893-901.
  • 9Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med, 2003, 348: 1764-1775.
  • 10Tobin G, Soderberg O , Thunberg U, et al. V (H)3-21 gene usage in chronic lymphocytic leukemia-characterization of a new subgroup with distinct molecular features and poor survival. Leuk Lymphoma, 2004, 45: 221-228.

同被引文献16

  • 1Rosén A,Bergh AC,Gogok P,et al.Lymphoblastoid cell line with B1 cellcharacteristics established from a chronic lymphocytic leukemia clone byin vitro EBV infection[J].Oncoimmunology,2012;1(1):18-27.
  • 2Hahne M, Kataoka T, Schr~ter M, et al. APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth [J]. J Exp Med, 1998, 188: 1185-1190.
  • 3Dillon SR, Gross JA, Ansell SM, et at. An APRIL to remember: novel TNF ligands as therapeutic targets[J]. Nat Rev Drug Discov, 2006, 5: 235-246.
  • 4Ingold K, Zumsteg A, Tardivel A, et al. Identification of proteoglycans as the APRIL-specific binding partners[J]. J Exp Med, 2005, 201: 1375-1383.
  • 5Hendriks J, Planelles L, de Jong-Odding J, et at. Heparan sulphate proteoglycan binding promotes APRIL-induced tumor cell proliferation[J]. Cell Death Diff, 2005, 12: 637-648.
  • 6Kern C, Cornuel JF, Billard C, et al. Involvement of BAFF and APRIL in the resistance to apoptosis of B-CLL through an autoerine pathway [J]. Blood, 2004, 103: 679-688.
  • 7Endo T, Nishio M, Enzler T, et al. BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappa B pathway[J]. Blood, 2007, 109: 703-710.
  • 8Planelles L, Castillo-Gutierrez S, Medema JP, et at. APRIL but not BLyS serum levels are increased in chronic lymphocytic leukemia: prognostic relevance of APRIL for survival[J]. Haematologica, 2007, 92: 1284-1285.
  • 9Bojarska-Junak A, Hus I, ChocholskaS, et al. BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features[J]. Leuk Res, 2009, 33:1319-1327.
  • 10Planelles L, Carvalho-Pinto CE, Hardenberg G, et al. APRIL ptomotes B-1 cell-associated neoplasm[J]. Cancer Cell, 2004, 6: 399-408.

引证文献2

二级引证文献11

白血病．淋巴瘤
2010年 第1期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部